Company intelligence / Profile preview

Auzone Biological Technology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Phase 3

Overview

Suzhou/Shanghai Auzone has developed an oral edaravone tablet, with a completed or ongoing Phase 3 trial in China for acute ischemic stroke and a BE clinical study planned in the US for ALS. The company is also developing therapies targeting nervous system, immune system, infectious, and metabolic diseases using small molecules, fusion proteins, and gene therapy modalities. Clinical results are not yet published but multiple trials are underway or recently completed.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecule drugsFusion proteinsAdeno-associated virus (AAV) based gene therapy
Industry: Biotech

Drug pipeline

1 asset

edaravone

Phase 3

Indications: Amyotrophic lateral sclerosis

Beyond the preview

Go deeper on Auzone Biological Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auzone Biological Technology.

Explore the full profile